Eli Lilly’s Tirzepatide (Mounjaro), Approved By FDA For Blood Glucose Control In Type 2 Diabetics; Obesity May Be Next Indication [Update] Eli Lilly’s tirzepatide (Mounjaro), showed substantial potential as an anti-obesity agent in a Phase 3 study released last month. Mounjaro was approved by FDA on May 13 to control blood glucose in diabetics. It could become a blockbuster, though it must overcome pricing and reimbursement hurdles.